Design Therapeutics (DSGN) Retained Earnings (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Retained Earnings of -$334.8 million for Q2 2026, down 26.82% year-over-year from -$457.5 million in Q2 2025, and down 6.41% on a QoQ basis from -$314.6 million in Q1 2026.
Design Therapeutics (DSGN) Retained Earnings (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Retained Earnings for 7 years, with the latest figure at -$334.8 million in Q2 2026.
- Retained Earnings for Q2 2026 came in at -$334.8 million, down 26.82% year-over-year; the trailing twelve-month figure through Jun 2026 was -$334.8 million (down 26.82% YoY), and the FY2025 annual result was -$297.0 million, down 30.72% from the prior year.
- Retained Earnings eased to -$334.8 million in Q2 2026, from -$314.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$60.7 million in Q1 2022 and troughed at -$334.8 million in Q2 2026.
- A 5-year average of -$196.1 million and a median of -$194.6 million in 2024 frame the typical range for Retained Earnings.
- The widest annual swing landed in 2022, when Retained Earnings tumbled 248.23%; it then retreated 26.82% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$110.8 million in 2022, then slumped by 60.36% to -$177.6 million in 2023, then slipped by 27.92% to -$227.2 million in 2024, then plunged by 30.72% to -$297.0 million in 2025, then decreased by 12.73% to -$334.8 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were -$334.8 million in Q2 2026, -$314.6 million in Q1 2026, and -$297.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | -334.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -334.81 Mn |
| Mar 31, 2026 | -314.64 Mn |
| Dec 31, 2025 | 403,000.00 |
| Sep 30, 2025 | -281.00 Mn |
| Jun 30, 2025 | -264.01 Mn |
| Mar 31, 2025 | -244.90 Mn |
| Dec 31, 2024 | -227.21 Mn |
| Sep 30, 2024 | -213.56 Mn |
| Jun 30, 2024 | -200.50 Mn |
| Mar 31, 2024 | -167,000.00 |
| Dec 31, 2023 | 62,000.00 |
| Sep 30, 2023 | -165.80 Mn |
| Jun 30, 2023 | -150.00 Mn |
| Mar 31, 2023 | -130.10 Mn |
| Dec 31, 2022 | -3.36 Mn |
| Sep 30, 2022 | -3.86 Mn |
| Jun 30, 2022 | -2.32 Mn |
| Mar 31, 2022 | -1.32 Mn |
| Dec 31, 2021 | -244,000.00 |
| Sep 30, 2021 | -4,000.00 |